DEA’s suspension of McKesson Corporation Retraction

Posted in Latest News on January 19, 2017.

The previous post, regarding the DEA’s suspension of McKesson Corporation’s sales of controlled substances from distribution in Florida, was found to be confusing. This suspension will impact one distribution center in Florida and impacts only the handling of hydromorphone. The Florida Department of Health and Division of Medical Quality Assurance apologizes for any confusion that may have resulted from that message. For specific details about McKesson’s agreement with the DEA, please contact the DEA. For questions about the potential impact of the sanctions in Florida, please contact the DOH’s Medical Quality Assurance.



More Latest News

Pharmacists May Order and Administer COVID-19 Tests
April 24, 2020

Emergency Order 20-006 allows a licensed pharmacist to order and administer FDA approved COVID-19 tests Continue reading


New Legislation Impacting Your Profession
April 15, 2020

Click here to view a full list of bill summaries from the 2020 Florida Legislative Session that may impact your profession. Continue reading